Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Collapse Important Safety Information
Expand Important Safety Information

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Prescribing Information DownloadPatient Websites HCP Websites menu

Visit Patient Site

View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Could It Be CSID?

Sucraid® Treats CSID

(Congenital Sucrase-
Isomaltase Deficiency)

Do you have patients suffering with unresolved IBS-like symptoms including gas, bloating, diarrhea, and/or nausea? Could it be CSID?

Download the Sucraid® 4-Day Trial Rx Form

This field is required.
Your download will begin shortly.
One or more fields have an error. Please check and try again.
There was an error. The form was not submitted.
Could It Be CSID?

Sucraid® Treats CSID

(Congenital Sucrase-Isomaltase Deficiency)

Do you have patients suffering with unresolved IBS-like symptoms including gas, bloating, diarrhea, and/or nausea? Could it be CSID?

Do you have patients with unresolved gas, bloating, diarrhea?

Could it be CSID?

CSID is largely a clinical diagnosis. Did you rule out Celiac disease and underlying conditions and surgical procedures where CSID may not be the primary cause of symptoms?

81

Consider a 4-Day Trial of Sucraid® at No Cost

In a clinical trial, 81% of patients became asymptomatic* with Sucraid®.1

*Patients who took Sucraid® with each meal were considered asymptomatic if they reported no watery stools and no or mild GI symptoms (gas, bloating, nausea, vomiting, abdominal cramps) for at least 7 of the 10 study days.

  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase Therapy for Congenital Sucrase-Isomaltase Deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142.
81

Consider a 4-Day Trial of Sucraid® at No Cost

In a clinical trial, 81% of patients became asymptomatic* with Sucraid®.1

*Patients who took Sucraid® with each meal were considered asymptomatic if they reported no watery stools and no or mild GI symptoms (gas, bloating, nausea, vomiting, abdominal cramps) for at least 7 of the 10 study days.

  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase Therapy for Congenital Sucrase-Isomaltase Deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142.

HOW SUCRAID® WORKS

Sucraid®:
The mechanism of action.

The active ingredient in Sucraid® is sacrosidase, which is a sucrase enzyme replacement. It splits sucrose into glucose and fructose, which facilitates absorption of both into the bloodstream from the small intestine.

Download the Sucraid® 4-Day Trial Rx Form

This field is required.
Your download will begin shortly.
One or more fields have an error. Please check and try again.
There was an error. The form was not submitted.

Call the Specialty Pharmacy for Information About Sucraid®

Therapeutic Response Trial

Sucraid® 4-Day Trial offers eligible patients a short therapeutic trial of Sucraid® to assess response in patients clinically diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID).

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.